DRD2 rs1800627: Understanding the TaqIB Genetic Variant
The rs1800627 variant, commonly known as the TaqIB polymorphism, is located within the DRD2 gene region. It has been extensively studied for its potential associations with dopamine receptor density, susceptibility to substance dependence, and individual responses to certain medications.
What each genotype means
Typical dopamine receptor density
This genotype is often referred to as the A2/A2 genotype in scientific literature. Research suggests individuals with this profile typically exhibit standard dopamine D2 receptor density in the brain compared to those carrying the A1 allele. Please note that associations between this variant and behavioral traits are complex and inconsistent across different studies.
This is the most common genotype, found in the majority of the global population.
Intermediate receptor density profile
This genotype, often called the A1/A2 genotype, represents a heterozygous state for the DRD2 TaqIB variant. Some studies suggest that carrying one copy of the A1 allele may be associated with a modest reduction in dopamine receptor binding sites, though findings remain mixed. If you have questions regarding how this might relate to medication response or behavioral health, please discuss them with your clinician or pharmacist.
This genotype is carried by a significant portion of the population, with frequencies varying by ancestry.
Reduced dopamine receptor density
This genotype is known in research as the A1/A1 genotype. Some studies have associated this profile with a roughly 30% reduction in dopamine D2 receptor density in the striatum, and it has been investigated for potential links to addiction susceptibility. Because these associations are statistically small and inconsistent across populations, please consult with a healthcare professional regarding any concerns about medication response or health traits.
This is the least common genotype, occurring in a minority of individuals across most global populations.
What is the rs1800627 Variant?
The rs1800627 variant, historically referred to as the TaqIB polymorphism, is a single nucleotide polymorphism (SNP) situated within the DRD2 gene locus. This gene encodes the dopamine D2 receptor, a critical protein in the brain's reward and motor control pathways. The variant is often studied alongside other nearby markers, such as the TaqIA polymorphism, because they frequently exist in linkage disequilibrium, meaning they are inherited together more often than would be expected by chance. Because it sits in a regulatory or structural region of the gene, researchers have long hypothesized that this specific change might influence how much dopamine receptor protein is produced or how effectively it functions in the brain. While it is a well-known marker in genetic research, it is important to note that the functional impact of this specific SNP remains a subject of ongoing scientific investigation rather than a settled biological fact.
The Role of the DRD2 Gene
The DRD2 gene provides instructions for creating the dopamine D2 receptor. This receptor is a G-protein coupled receptor that plays a central role in the dopaminergic system, which regulates mood, motivation, reward, and movement. By inhibiting adenylyl cyclase activity, the D2 receptor helps modulate the transmission of signals between neurons. Because dopamine signaling is fundamental to how the brain processes pleasure and reinforcement, variations in the DRD2 gene are frequently investigated in the context of psychiatric and neurological conditions. Antipsychotic medications, which are used to treat conditions like schizophrenia, often work by binding to and blocking these D2 receptors. Consequently, genetic variations that alter the density or sensitivity of these receptors are of significant interest to pharmacogeneticists, who study how an individual's genetic makeup might influence their response to specific therapeutic drugs.
Research Associations and Evidence Strength
Research into rs1800627 has produced mixed and sometimes controversial results. Some studies have suggested that specific alleles of the TaqIB polymorphism are associated with an increased risk of substance dependence, such as heroin addiction, though these findings have varied significantly between different ethnic populations. Other research has explored whether this variant influences the risk of Parkinson's disease or the clinical efficacy of antipsychotic medications. However, the evidence strength for these associations is generally considered limited. Many studies have been small, and results often fail to replicate across diverse cohorts. Furthermore, because rs1800627 is often in linkage disequilibrium with other nearby variants, it is difficult for researchers to determine if this specific SNP is the true driver of an observed effect or if it is simply a 'tag' for another functional variant nearby. As such, these associations should be viewed as statistical correlations rather than definitive causal links.
Population Frequency
The minor allele (A) of the rs1800627 variant is found at a frequency of approximately 0.15 to 0.25 across various global populations. This means that a significant portion of the human population carries at least one copy of this allele, making it a relatively common genetic variation. Because the frequency can fluctuate based on ancestral background, researchers must be careful to account for population stratification when conducting genetic association studies. The presence of this variant in a large percentage of the population underscores that it is a normal part of human genetic diversity rather than a rare mutation. However, the clinical relevance of carrying a specific genotype remains highly dependent on the context of the individual's overall genetic background and environmental factors.
Interpreting Your Genetic Information
It is important to understand that genetic variants like rs1800627 do not act in isolation. Human traits and responses to medication are complex, influenced by a combination of hundreds of genetic variants, lifestyle factors, and environmental exposures. Having a particular genotype for this SNP does not mean you will develop a specific condition or respond to a medication in a predictable way. If you are curious about how your genetics might influence your health or your response to a prescribed medication, you should discuss this information with your clinician or a qualified pharmacist. They are the only ones who can interpret genetic data in the context of your full medical history and current treatment plan. Never make changes to your medication or health regimen based on genetic test results without professional medical guidance.
How common is this variant?
The minor allele (A) frequency is approximately 0.15-0.25 across global populations, meaning the variant is common and widely distributed.
Frequently asked questions
Is rs1800627 a diagnostic test for addiction?
No. Genetic variants like rs1800627 are not diagnostic tools. Addiction is a complex condition influenced by many genetic, environmental, and social factors, and no single SNP can predict or diagnose it.
Does this variant determine how I respond to antipsychotics?
While some research suggests a potential link between DRD2 variants and medication response, the evidence is not strong enough to use this SNP for clinical decision-making. Always consult your doctor regarding your medication.
What is the difference between TaqIA and TaqIB?
TaqIA (rs1800497) and TaqIB (rs1800627) are two different SNPs located near or within the DRD2 gene region. They are often studied together because they are frequently inherited together, but they are distinct genetic markers.
Can I change my risk by knowing my genotype?
Knowing your genotype does not change your biological risk. Health outcomes are determined by a combination of factors, and you should focus on evidence-based lifestyle choices and professional medical advice.
Sources & further reading
Educational information only, last refreshed 10/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1800627?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in DRD2
This SNP in the DRD2 gene is frequently studied in the context of psychiatric genetics, particularly regarding dopamine receptor expression and schizophrenia risk.
This variant has been studied for its association with schizophrenia and dopaminergic signaling.
The TaqIB polymorphism in the DRD2 gene is associated with dopamine receptor density and various behavioral and reward-related traits.
A synonymous coding variant in exon 7 of DRD2 that affects mRNA stability, translation kinetics, and dopamine-related working memory and reward phenotypes.
Known as the DRD2 TaqID polymorphism, this variant alters D2 dopamine receptor gene structure and is implicated in altered striatal dopamine functioning and substance use behavior.
A rare variant identified in the DRD2 gene, which is involved in the regulation of stress-induced behavioral responses.